Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDC002
- Development stage
- Preclinical
- Lead developer
- Mitodicure
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MDC002 is a preclinical small molecule therapeutic being developed by Mitodicure. It is designed to target both the Na+/K+-ATPase and the mitochondrial sodium-calcium exchanger (NCLX), aiming to restore cellular and mitochondrial ion balance. The drug is currently being investigated for a broad range of conditions characterized by mitochondrial dysfunction and fatigue, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia, Gulf War syndrome, and chronic Lyme disease. Mitodicure is also exploring its potential in rare genetic and autoimmune disorders such as Marfan syndrome, Ehlers-Danlos syndromes, and ANCA vasculitis.
02
Targets
NCX (Sodium/calcium exchanger 3)
Beyond the preview
Go deeper on MDC002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDC002.